Sotagliflozin is an SGLT1 and SGLT2 inhibitor. It is only licensed for type 1 diabetes, not for type 2 diabetes.
Dapagliflozin was endorsed by NICE in Aug 19 as a treatment for type 1 diabetes. Sotagliflozin has exactly the same restrictions on its use. It improves HbA1c, brings greater weight loss and improves quality of life. It is presumed that this drop in HbA1c will lead to a lower risk of complications from diabetes, though this hasn’t yet been shown.